GIP and diabetes mellitus: Several diabetes drugs have been trialed as management strategies for HFpEF, including the GIP (glucose-dependent insulinotropic polypeptide) and GLP1 agonists—semaglutide and tirzepatide—and SGLT inhibitors—dapagliflozin and empagliflozin.